Trial Profile
An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Pediatric Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), and in Pediatric and Adult Patients With Congenital Myasthenic Syndromes (CMSs)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Amifampridine (Primary)
- Indications Congenital myasthenic syndromes
- Focus Expanded access; Therapeutic Use
- Sponsors Catalyst Pharmaceuticals
- 05 Dec 2019 Status changed from recruiting to completed.
- 27 May 2014 New trial record
- 23 Apr 2014 Programme enrolment will begin in the next few months, pending US FDA review and approvals, according to a Catalyst Pharmaceutical Partners media release.